The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. We asked, How to select maintenance therapies post-autologous stem cell transplant (ASCT) for patients with high-risk MM? In this expert discussion, Shaji Kumar and Naresh Bumma provide their insights into post-ASCT maintenance therapy for high-risk patients. The experts consider the use of lenalidomide as a monotherapy versus in combination with...

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status? In this podcast, Hira Mian discusses the relationship between age and frailty status, sharing her perspective on how they may inform treatment strategies for patients with multiple myeloma. Mian examines the influence of age on frailty status, but notes other influential factors featured in the International Myeloma...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy Schmidt, University of Wisconsin-Madison, Madison, US. We asked, How is the immune reconstitution in patients who stop therapy after achieving minimal residual disease (MRD) negativity? In this interview, Schmidt discusses their poster presented at ASH 2022 entitled: Humoral immune reconstitution following therapy with daratumumab, carfilzomib,...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paulo, BR. We asked, What are the main discrepancies between multiple myeloma (MM) treating centers in Brazil? In this podcast, Hungria discusses their poster presented at ASH 2022 entitled: A Brazilian real-life experience of multiple myeloma patients: Final results from the Mmybrave multi-center...

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease? In this podcast, Beksac discusses their poster presented at ASH 2022 entitled: Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with...

During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Ostrava, CZ. We asked, Which patients might benefit the most from isatuximab-based combinations in the relapsed setting? Hájek begins by explaining that isatuximab is an anti-CD38 monoclonal antibody currently approved for treatment in combination with pomalidomide + dexamethasone or carfilzomib + dexamethasone. This is followed by a discussion on...

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also featured Nina Shah, Paul Richardson, Morie Gertz, and Heinz Ludwig. The topic of this discussion was “Integrating B-cell maturation antigen (BCMA)-directed agents in the treatment landscape for relapsed/refractory multiple myeloma”, which was identified as an unmet need within multiple myeloma treatment. Mateos begins the discussion by posing the...

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria Mateos, Nina Shah, Paul Richardson, and Elena Zamagni. The topic of this discussion was “The role of consolidation after autologous stem cell transplantation”, which was identified as an unmet educational need within multiple myeloma treatment. Gertz begins the discussion by explaining that patients often have confusion over what...

During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma?  Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare...

During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal antibodies to treat relapsed/refractory multiple myeloma? Mateos begins by giving an overview of the bispecific antibodies, talquetamab and teclistamab. These antibodies have been investigated in combination with daratumumab in two clinical trials; Mateos...

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Boston, US, and Peter Voorhees, Levine Cancer Institute, Charlotte, US. We asked, Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM): What have we learned from GRIFFIN and CASSIOPEIA trials? In this podcast, Laubach and Voorhees discuss the findings from the randomized phase II GRIFFIN...

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel immunotherapies: Prevention, treatment, and impact on the quality of life of patients with multiple myeloma. Raje and Delforge discuss the management of infections with novel immunotherapies, including: monoclonal antibodies,...

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? This podcast captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding...

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control. In this podcast, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently...

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context? In this podcast, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and...

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Columbia University, New York, US. We asked, The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far? The podcast focuses on both hematologic and organ response in amyloidosis, as well discussing the findings of a recent study. See acast.com/privacy for privacy and opt-out information.

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answered: Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure? In this podcast, Mateos discusses the progression of monoclonal gammopathy of undetermined significance (MGUS) and SMM to MM from a...

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR, answered: Does 'cure' have a different meaning in MM? In this podcast, Mohty discusses how the word 'cure' has different implications for young and older patients, and discusses the functional/operational cure for patients with standard-...

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)? In this podcast, Mo and Nadeem discuss factors to be considered with regimen options for patients with lenalidomide-refractory MM. They discuss cardiac risk factors, lines of therapy, prognosis, and end the podcast on the topic of new agents. See...

During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk multiple myeloma (MM)? In this podcast, Sonneveld discusses trial results presented during EHA2021 on the efficacy of novel treatments for patients with high-risk MM, a patient group associated with poor outcomes and shorter remission rates. He...

During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Leleu, Poitiers University Hospital, Poitiers, FR. We asked, When BCMA-directed therapy is not an option, how should we treat late relapse? Leleu discusses three alternatives to anti-B-cell maturation antigen (BCMA) directed therapies, including alternative drugs (provided the patient is nonrefractory), enrolment to clinical trials investigating...

During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, US. We asked, What do you need to remember when facing CAR T-cell toxicities? In this podcast, McCarthy discusses the two main chimeric antigen receptor (CAR) T-cell toxicities: cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). Initially, McCarthy lists what to look out for in terms of...

During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma? Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it’s precursor stages, and changes to treatment regimens for...

During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, and Professor Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, If maintenance after induction reduces therapy options at relapse, is it still worth it? Currently, the only approved maintenance therapy for multiple myeloma is lenalidomide. When answering whether this treatment is worth it, Jackson provides meta-analysis results of the...